Author:
Tian Mei,Civelek A. Cahid,Carrio Ignasi,Watanabe Yasuyoshi,Kang Keon Wook,Murakami Koji,Garibotto Valentina,Prior John O.,Barthel Henryk,Zhou Rui,Hou Haifeng,Dou Xiaofeng,Jin Chentao,Zuo Chuantao,Zhang Hong,
Abstract
Abstract
Purpose
Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18F-flortaucipir PET imaging.
Method
A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting.
Conclusion
This international consensus and practice guideline will help to promote the standardized use of 18F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.
Funder
National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献